SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-20-004486
Filing Date
2020-04-02
Accepted
2020-04-01 19:25:26
Documents
8
Period of Report
2020-05-18
Effectiveness Date
2020-04-02

Document Format Files

Seq Description Document Type Size
1 DEF 14A sgmo_proxyx2020xdef.htm DEF 14A 1528750
2 macraesignaturea02.jpg GRAPHIC 28251
3 sgmocdagraphiccashinc01.jpg GRAPHIC 99051
4 sgmocdagraphicceo2019a02.jpg GRAPHIC 43356
5 sgmocdagraphicfactors.jpg GRAPHIC 56944
6 sgmocdagraphicprimarya01.jpg GRAPHIC 54098
7 sgmoproxycardp1a01.jpg GRAPHIC 195814
8 sgmoproxycardp2a01.jpg GRAPHIC 115600
  Complete submission text file 0001628280-20-004486.txt   2325945
Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

IRS No.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-30171 | Film No.: 20767000
SIC: 2836 Biological Products, (No Diagnostic Substances)